Buy
Sell
Share Name Share Symbol Market Type
Regeneron Pharmaceuticals Inc NASDAQ:REGN NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  12.00 2.0% 611.4655 611.35 611.87 612.22 591.67 602.20 885,210 19:31:44

Sanofi, Regeneron See Positive Results From Dupixent Phase 3 Trial

23/05/2020 12:34am

Dow Jones News


Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart


From May 2020 to Jun 2020

Click Here for more Regeneron Pharmaceuticals Charts.

By Kimberly Chin

 

Sanofi SA and Regeneron Pharmaceuticals Inc. said it had positive results for an advanced trial of a treatment for patients with a chronic, allergic inflammatory disease of the esophagus.

The Phase 3 trial of Dupixent met both its co-primary endpoints, as well as important secondary endpoints, the companies said. The trial had 81 patients, ages 12 years and older, who had eosinophilic esophagitis.

The patients were able to show clinical and anatomic improvements, including the ability to swallow. Patients saw a 69% reduction in disease symptoms, as well as a 60% reduction in their esophageal eosinophilic count to a normal range, the companies said.

Eosinophilic esophagitis damages the esophagus and impairs its functions, making it difficult to swallow. It could also damage and scar the esophagus without treatment.

This was the first and only biologic to show "positive and clinically meaningful results" in an advanced trial, the companies said.

 

Write to Kimberly Chin at kimberly.chin@wsj.com

 

(END) Dow Jones Newswires

May 22, 2020 19:19 ET (23:19 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

1 Year Regeneron Pharmaceuticals Chart

1 Year Regeneron Pharmaceuticals Chart

1 Month Regeneron Pharmaceuticals Chart

1 Month Regeneron Pharmaceuticals Chart
ADVFN Advertorial
Your Recent History
NASDAQ
REGN
Regeneron ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20200602 18:46:52